Dihydroergotamine
A dopamine and serotonin agonist with sympatholytic activity.
General information
Dihydroergotamine is used for the treatment of orthostatic hypotension and migraine (ChEBI).
Dihydroergotamine on DrugBank
Dihydroergotamine on PubChem
Dihydroergotamine on Wikipedia
Marketed as
MIGRANAL (DIHYDROERGOTAMINE MESYLATE); DIHYDROERGOTAMINE MESYLATE; D.H.E. 45 (DIHYDROERGOTAMINE MESYLATE); DIHYDERGOT; ERGONT; ERGOTONIN; IKARAN; ORSTANORM; VERLADYN
C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials
|
in silico | 3.31 | Aug/05/2020 | |
|
In silico screening of FDA approved drugs reveals ergotamine and dihydroergotamine as potential coronavirus main protease enzyme inhibitors
3CLpro Small molecule In silico |
in silico | 2.80 | Predicted potent binding to the catalytic site of the SARS-CoV-2 3C-like protease. |
Jun/10/2020 |
|
In silico identification of drug candidates against COVID-19
3CLpro RdRpol |
in silico | 2.11 | Predicted to inhibit the SARS-CoV-2 3C-like protease. |
Oct/20/2020 |
